Annexon, Inc. (ANNX)
After hours:
| Previous close | 4.6600 |
| Open | 4.7500 |
| Bid | 4.8400 x 300 |
| Ask | 4.9100 x 200 |
| Day's range | 4.6900 - 5.0600 |
| 52-week range | 1.5700 - 8.4000 |
| Volume | |
| Avg. volume | 1,742,774 |
| Market cap | 444.77M |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.7700 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.60 |
ZacksAnnexon (ANNX) to Report Q1 Earnings: What's in the Cards?
Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.
GlobeNewswireAnnexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation New preclinical data on the pathogenic role of C1q on photoreceptor synapse elimination and the protection of photoreceptors and their function from C1q blockade in GA will be featured as a poster presentation BRISBANE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company
ZacksDown -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX)
Annexon (ANNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
